miRagen Therapeutics (Boulder, CO) a preclinical-stage biopharmaceutical company focused on the development of miRNA therapeutics for cardiovascular and muscle diseases, closed a $4 Series B, bringing the total round financing to $12M. Participants include Boulder Ventures, Amgen Ventures, Broadview Ventures, The Peierls Foundation and Atlas Venture.

Control Medical Technology (Park City, UT) a medical device company mechanical, rotational vacuum assisted and ergonomic improvements of single-handed fluid, pathology, and tissue aspirator, closed a $3M Series A financing. Participants include Spring Bay Ventures.
*Estimated capital raise

Clovis Oncology (Boulder, CO) an entity focused on licensing or acquiring rights to oncology compounds in all stages of clinical development, closed a $145M Series A financing. Participants include Domain Associates, New Enterprise Associates, Versant Ventures, Aberdare Ventures, Abingworth, Frazier Healthcare Ventures, and ProQuest Investments.

OPX Biotechnologies (Boulder, CO) a research-stage biofuels company using synthetic biology to engineer the microbes as a renewable fuel source, added to their Series B financing bringing the round up to $17.5M. Participants include Braemar Energy Ventures, Altira Group, Mohr Davidow Ventures and X/Seed Capital.

CeraPedics (Broomfield, CO) a clinical stage device company focused on osteobiologic products for bony voids, closed a $15M Series B financing. Participants include NGN Capital and OrbiMed Advisors.

BiOptix (Boulder, CO) a commercial focused developer of an array-based biomolecule detection system that addresses many markets that currently cannot obtain the needed sensitivity and throughput in a single solution, closed a $3M Series A finacing. Participants include Boulder Ventures.

OPX Biotechnologies (Boulder, CO) a research-stage biofuels company using synthetic biology to engineer the microbes as a renewable fuel source closed a $12.1M Series B financing. Participants include Braemar Energy Ventures, Mohr Davidow Ventures and X/Seed Capital.

MD-IT (Boulder, CO) pprovider of medical documentation services and software for physician offices and ambulatory clinics, closed a $11M Series B financing. Participants include J. Burke Capital Partners.

Accera (Broomfield, CO) a biotechnology company developing therapies that address metabolic deficiencies and provide an alternative energy source for brain cells, closed a $35M Series C financing. Participants include Inventages Venture Capital, POSCO BioVentures and Bloodstone Ventures.

Prolexys Pharmaceuticals (Salt Lake City, UT) early-stage developer of cancer and cardiovascular small molecule drugs, closed a $20M Series A financing. Participants include Friedli Corporate Finance.

MicroPhage (Longmont, CO) early-stage developer of bacteriophage-based bacterial identification and antibiotic susceptibility and resistance testing, closed $11M Series A financing.
Participants include ?

AlloCure (Germany, UT) a cell therapy company focused on acute kidney injury closed a $14.5M Series A financing. Participants include SV Life Sciences and Novo AS.

Sierra Neuropharmaceuticals (Aurora, CO) development-stage biopharmaceutical company specializing treating neurological disorders, closed a $21.5M Series A financing. Participants include HealthCare Ventures, Morgenthaler Ventures, Sequel Ventures and High Country Venture.